Skip to content

Ardent Health Partners ARDT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Tenet Healthcare logo
Tenet HealthcareTHC
$5.12B+6.2%
Surgery Partners, Inc. logo
Surgery Partners, Inc.SGRY
$2.55B+0.9%
Teladoc Health logo
Teladoc HealthTDOC
$17.87B+0.4%
National Healthcare logo
National HealthcareNHC
$233.64M+0.2%
Astrana Health logo
Astrana HealthASTH
$477.51M+5.5%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$1.96B+4.5%

Other financials

Income statement

See full
Revenue$1.6B+7.0%
Gross profit$1.6B+6.7%
Net income$39.9M-3.7%
EPS (diluted)$0.28-3.4%

Balance sheet

See full
Cash & equivalents$609.7M+23.2%
Total debt$1.2B+1.7%
Total equity$1.3B+13.8%
Total assets$5.3B+7.0%

Cash flow

See full
Operating cash flow-$60.2M-143%
CapEx$28.1M+22.6%
Free cash flow-$88.3M-85.2%

Valuation

See full
Market cap$1.35B-37.7%
Enterprise value$1.91B-31.9%
P/E10×+0.4×
P/S0.2×-0.1×

Profitability

See full
Gross margin97.5%-0.1pp
Net margin2.1%-1.6pp
FCF margin3.4%+1.4pp

Returns & leverage

See full
Return on equity10.7%-9.0pp
Debt / equity0.9×-0.1×
Current ratio2.1×0.0×

Where this comes from

Reported directly by Ardent Health Partners in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Ardent Health Partners’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardent Health Partners's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardent Health Partners's additional paid-in capital?
Ardent Health Partners (ARDT) reported additional paid-in capital of $796.39M in Q1 2026.
How has Ardent Health Partners's additional paid-in capital changed year-over-year?
Ardent Health Partners's additional paid-in capital increased by 4.4% year-over-year, from $762.62M to $796.39M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.